Arrowhead Pharmaceuticals (ARWR) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 68.3% versus a loss of 12.5%. Over five years, RDY leads with a -7.1% price change compared with -7.1% for ARWR. Dr. Reddy's Laboratories is the larger company by market cap ($10.16 billion vs $8.58 billion), about 1.2 times the size, while Arrowhead Pharmaceuticals is growing revenue faster (+23258.2% vs +13.8%).
Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Arrowhead Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | RDY |
|---|---|---|
| Share price | $60.74 | $12.20 |
| Market cap | $8.58B | $10.16B |
| 1-day change | -1.20% | -0.57% |
| YTD return | -7.40% | -12.61% |
| 1-year return | +68.25% | -12.54% |
| 5-year return | -7.07% | -7.06% |
| P/E ratio (TTM) | — | 27.73 |
| Forward P/E | — | 18.94 |
| EPS (TTM) | $-2.28 | $0.44 |
| Dividend yield | 0.00% | 65.57% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $829.45M | $3.81B |
| Revenue growth (YoY) | +23258.15% | +13.76% |
| Net income (latest FY) | $-1.63M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | 11.86% | 22.09% |
| Net margin | -0.20% | 17.40% |
| 52-week high | $95.49 | $15.67 |
| 52-week low | $34.61 | $11.36 |
| Distance from 52-week high | -36.39% | -22.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +76.54% | +8.36% |
| Average volume | 1.90M | 2.89M |
| Shares outstanding | 141.25M | 832.99M |
| Employees | 711 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed RDY by 80.8 percentage points over the past year.
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.57% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -0.2 cents for Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +13.76%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
ARWR vs RDY FAQ
Which is bigger, Arrowhead Pharmaceuticals or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $10.16B compared with $8.58B for Arrowhead Pharmaceuticals (ARWR).
Which stock has performed better over the past year, ARWR or RDY?
ARWR returned +68.25% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Arrowhead Pharmaceuticals or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Arrowhead Pharmaceuticals does not currently pay a regular dividend.
Are Arrowhead Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.